Table 1.
Demographic and baseline comorbidities of COVID-19 patients attending our hospital during the first wave of the pandemic (1 March to 1 June 2020), and for whom we had information on clinical outcomes after a year. Characteristics of patients who were discharged from the emergency room and those who were admitted to hospital are compared.
| Total (n = 766) |
Discharged from the Emergency Room (n = 321) |
Admitted to Hospital (n = 445) |
p-Value | ||
|---|---|---|---|---|---|
| Mean age at admission, years (SD; rank) | 65.1 (17.5; 18–98) | 56.2 (17.8; 18–96) | 71.5 (14.3; 20–98) | <0.001 | |
| Age group | Over 65 years old, n (%) | 418 (54.6%) | 104 (32.4%) | 314 (70.6%) | <0.001 |
| Younger than 65 years old, n (%) | 348 (45.4%) | 217 (67.6%) | 131 (29.4%) | ||
| Sex | Male, n (%) | 388 (50.7) | 177 (55.1) | 201 (45.2) | 0.006 |
| Female, n (%) | 378 (49.3) | 144 (44.9) | 244 (54.8) | ||
| Nursing home residents, n (%) | 75 (9.8) | 11 (3.4) | 64 (14.4) | <0.001 | |
| Previous comorbidities | Arterial hypertension, n (%) | 401 (52.3) | 101 (31.5) | 300 (67.4) | <0.001 |
| Diabetes, n (%) | 189 (24.7) | 39 (12.1) | 150 (33.7) | <0.001 | |
| Dyslipidemia, n (%) | 184 (24) | 48 (15) | 136 (30.6) | <0.001 | |
| Obesity, n (%) | 139 (18.1) | 45 (14) | 94 (21.1) | 0.012 | |
| Chronic kidney disease, n (%) | 70 (9.1) | 9 (2.8) | 61 (13.7) | <0.001 | |
| Cognitive impairment, n (%) | 69 (9) | 15 (4.7) | 54 (12.1) | <0.001 | |
| Ischemic heart disease, n (%) | 66 (8.6%) | 7 (2.2%) | 59 (13.3) | <0.001 | |
| Oncological disease, n (%) | 66 (8.6%) | 18 (5.6%) | 48 (10.8%) | 0.012 | |
| Sleep apnea/hypopnea syndrome, n (%) | 62 (8.1%) | 17 (5.3%) | 45 (10.1%) | 0.016 | |
| Hypothyroidism, n (%) | 61 (8%) | 22 (6.9%) | 39 (8.8%) | 0.335 | |
| Cerebrovascular diseases, n (%) | 56 (7.3%) | 9 (2.8%) | 47 (10.6%) | <0.001 | |
| Depressive syndrome, n (%) | 54 (7%) | 18 (5.6%) | 36 (8.1%) | 0.185 | |
| Chronic obstructive pulmonary disease, n (%) | 53 (6.9%) | 11 (3.4%) | 42 (9.4%) | 0.001 | |
| Bronchial asthma, n (%) | 51 (6.7%) | 25 (7.8%) | 26 (5.8%) | 0.287 | |
| Anemia, n (%) | 37 (4.8%) | 8 (2.5%) | 29 (6.5%) | 0.010 | |
| Chronic liver disease, n (%) | 34 (4.4%) | 8 (2.5%) | 26 (5.8%) | 0.026 | |
| Congestive heart failure, n (%) | 34 (4.4%) | 3 (0.9%) | 31 (7%) | <0.001 | |
| Connective tissue disorder, n (%) | 26 (3.4%) | 12 (3.7%) | 14 (3.1%) | 0.655 | |
| Blood dyscrasias, n (%) | 26 (3.4%) | 5 (1.6%) | 21 (4.7%) | 0.017 | |
| Peripheral vascular disease, n (%) | 18 (2.3%) | 3 (0.9%) | 15 (3.4%) | 0.028 | |
| Hyperuricemia, n (%) | 26 (3.4%) | 8 (2.5%) | 18 (4%) | 0.242 | |
| Any previous comorbidity, n (%) | 596 (77.8%) | 196 (61.1%) | 400 (89.9%) | <0.001 | |